Skip to main content
SpringerLink
Log in

Lebrikizumab safe in adolescents and adults with atopic dermatitis

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Stein Gold L, et al. Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials. . American Journal of Clinical Dermatology 24: No. 3, 17 May 2023. Available from: URL: http://doi.org/10.1007/s40257-023-00792-6

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lebrikizumab safe in adolescents and adults with atopic dermatitis. Reactions Weekly 1958, 8 (2023). https://doi.org/10.1007/s40278-023-39682-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-39682-5

Search

Navigation